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Toxicity testing is vital to protect human health from exposure to toxic chemicals in the environment.
Furthermore, combining novel cellular models with molecular profiling technologies, such as
metabolomics can add new insight into the molecular basis of toxicity and provide a rich source of
biomarkers that are urgently required in a 21st Century approach to toxicology. We have used an
NMR-based metabolic profiling approach to characterise for the first time the metabolome of the
RPTEC/TERT1 cell line, an immortalised non-tumour human renal epithelial cell line that
recapitulates phenotypic characteristics that are absent in other in vitro renal cell models.
RPTEC/TERT1 cells were cultured with either the dosing vehicle (DMSO) or with exposure to one of
six compounds (nifedipine, potassium bromate, monuron, D-mannitol, ochratoxin A and sodium
diclofenac), several of which are known to cause renal effects. Aqueous intracellular and culture media
metabolites were profiled by 1H NMR spectroscopy at 6, 24 and 72 hours of exposure to a low effect
dose (IC10). We defined the metabolome of the RPTEC/TERT1 cell line and used a principal
component analysis approach to derive a panel of key metabolites, which were altered by chemical
exposure. By considering only major changes (1.5 fold change from control) across this metabolite
panel we were able to show specific alterations to cellular processes associated with chemical treatment.
Our findings suggest that metabolic profiling of RPTEC/TERT1 cells can report on the effect of
chemical exposure on multiple cellular pathways at low-level exposure, producing different response
profiles for the different compounds tested with a greater number of major metabolic effects observed
in the toxin treated cells. Importantly, compounds with established links to chronic renal toxicity
produced more diverse and severe perturbations to the cellular metabolome than non-toxic compounds
in this model. As these changes can be rationalised with the different pharmacological and toxicity
profiles of the chemicals it is suggested that metabolic profiling in the RPTEC/TERT1 model would be
useful in investigating the mechanism of action of toxins at a low dose.
Introduction
Toxicity testing is vital to protect human health from exposure
to toxic chemicals in both the clinic and the wider environment,
however the process is still faced with many significant
challenges. The core battery of tests for hazard identification
and risk assessment are heavily reliant on extrapolation of
observations in animal models to man, a process that is
inherently costly, inaccurate and ethically undesirable. Direct
assessment of the effects of environmental toxicants in human
populations is very difficult as exposure is often at a low
concentration and responses are often subtle, early events.
Yet there is increasing public and legislative pressure to fill the
knowledge gap that exists for many widely used chemicals in
terms of possible impacts on human health, for example the
Registration, Evaluation, Authorisation and Restriction of
Chemicals (REACH) initiative in effect across European
Union countries from 2007 (http://ec.europa.eu/enterprise/
sectors/chemicals/reach/index_en.htm). In the face of these
challenges, there are growing calls to make more use of
human-derived cell models coupled to high-throughput
a Biomolecular Medicine, Department of Surgery and Cancer,
Faculty of Medicine, Imperial College London, Sir Alexander
Fleming Building, South Kensington, London, SW7 2AZ, UK.
E-mail: h.keun@imperial.ac.uk, t.ebbels@imperial.ac.uk
bUCD School of Biomolecular & Biomedical Sciences,
UCD Conway Institute, University College Dublin, Dublin, Ireland
cMRC-HPA Centre for Environment & Health, Department of
Epidemiology and Biostatistics, School of Public Health,
Faculty of Medicine, Imperial College London, London, UK
dDivision of Physiology, Department of Physiology and Medical Physics,
Innsbruck Medical University, Innsbruck, Austria
w Electronic supplementary information (ESI) available: Full details
of the effect of toxin treatment on metabolite concentration and full








































View Article Online / Journal Homepage / Table of Contents for this issue
248 Mol. BioSyst., 2011, 7, 247–257 This journal is c The Royal Society of Chemistry 2011
molecular profiling platforms that can predict adverse effects
by reporting on key cellular pathways that are perturbed by
toxicants, i.e. ‘toxicity pathways’ defined at the molecular level
(‘Toxicity testing in the 21st century: a vision and a strategy’:
National Research Council (U.S.). Committee on Toxicity
Testing and Assessment of Environmental Agents).1 Metabolic
profiling (metabolomics/metabonomics) is one such strategy
for cellular pathway analysis based on the untargeted analysis
of the small molecule composition of a biological sample and
is a powerful and flexible tool in biomarker discovery.2,3
Metabolic profiling techniques have been widely applied in
the field of toxicology,4 mainly in the context of animal studies
where urine or plasma have been analysed. NMR-based
metabolomic studies have shown that urine analysis can
predict if the kidney is a major target organ for potential
toxicants5 and can reveal distinct patterns of metabolic
perturbations in response to site-specific nephrotoxins.6
1H NMR spectroscopy has also been used to study human
kidney tissue (both carcinoma and normal)7,8 and specific
osmolytes have been measured in non-tumour animal renal
lines.9 The integration of an in vitro cell model and metabolic
profiling techniques allow the study of the intracellular
metabolome and its interaction with the culture media in
response to a chemical exposure. The utilisation of a human
derived cell model would allow chemical screening of potentially
toxic chemicals that would not require cross-species correction
and may be informative of a chemicals mechanism of toxicity.
We have previously demonstrated that our NMR-based
approach can be utilised to study the endogenous metabolome
of an in vitro cell system and observe changes in response to
chemical exposure.10
Renal Proximal Tubule Epithelial Cells (RPTECs) are
polarised cells that line the tubule of the kidneys and possess
a high metabolic activity. They are involved in blood clearance
and resorption of essential metabolites and macromolecules
from the glomerular ultrafiltrate.11 The study of human
RPTEC cells in primary culture is difficult as these cells enter
senescence after approximately 20 population doublings.12
However the development of human derived cell lines can
over come this issue. The RPTEC/TERT1 cell line is a novel
non-cancer derived human cell model, which contains no viral
oncogenes but has been immortalised by over expression of
human telomerase (hTERT).12 Characterisation of RPTEC/
TERT1 cells has already revealed morphological and bio-
chemical properties that show an improved retention of
in vivo phenotype e.g. formation of tight junctions and
microvilli, and RPTEC specific sodium-dependent phosphate
transporters expression.12 In addition, these cells are
maintained under serum-free conditions. Thus the cell line has
many potential applications in toxicology, tissue engineering,
basic cell biology and drug screening.12 In the present study
we used an NMR based metabolic profiling approach to
characterise the metabolome of the human RPTEC/TERT1
cell line and define the response of the system over a 72 hour
period to low-level exposure to a selection of model compounds
that affect the kidney. The current study was carried out within
the EU funded Framework Program 6 carcinoGENOMICS
project,13 which aims to develop omics-based in vitro screens
for chemical carcinogens. We show here that the novel
RPTEC/TERT1 in vitro cell model possesses metabolomic
characteristics, specifically intracellular accumulation of renal
osmolytes, that indicate preserved in vivo functions. Furthermore
we observed that exposure to renal toxicants with different
pharmacological and toxicity profiles, at levels that are
not grossly cytotoxic, produced contrasting perturbations to
metabolism that reflect specific physiological effects—a
pre-requisite for the use of this approach in toxicity testing.
Methods
Chemicals and reagents
All cell culture plastics were from Costar. All reagents
(including nifedipine, D-mannitol, sodium diclofenac, monuron,
ochratoxin A and potassium bromate) were of the highest
available purity from commercial sources.
RPTEC/TERT1 culture and harvesting
The human renal proximal tubular epithelial cell line, RPTEC/
TERT1 was originally obtained from the developing laboratory
of Dr. Grillari-Voglauer (Institute of Applied Microbiology,
BOKU-University of Natural Resources and Applied Life
Sciences, Vienna 12). Cells were maintained in Dulbecco’s
modified Eagle’s medium Nutrient Mix F12 (1 : 1) (Gibco)
containing 2 mM L-Glutamine (Gibco), 36 ng mL1 hydro-
cortisone (Sigma), 10 ng mL1 recombinant human epidermal
growth factor (EGF, Sigma), 50 U mL1 penicillin, 50 mg mL1
streptomycin (Gibco), 5 mg mL1 insulin, 5 mg mL1 transferrin
and 5 ng mL1 selenium (ITS(Sigma)). Culture medium was
replaced with freshmedium every 48 hours. Cells were maintained
in 75 cm2 Costar flasks at 37 1C in a humidified atmosphere
containing 95% air and 5% CO2. For compound treatments,
cells were grown to confluency and cultured for 10 days prior
to experimentation. Control cells were exposed to an appropriate
concentration of vehicle control (0.1% v/v dimethyl sulfoxide
(DMSO)). Cells were exposed to the indicated test compound
(nifedipine (10 mM), D-mannitol (10 mM), sodium diclofenac
(30 mM), monuron (200 mM), ochratoxin A (300 nM), potassium
bromate (200 mM)) for 6, 24 or 72 hours.
For metabolite analysis (at 6, 24 and 72 h), 1 mL of the
culture media was transferred to a fresh Eppendorft tube,
centrifuged (10 000 rpm, 5 min) to remove dead cells and
stored at 80 1C for subsequent analysis. The remaining
media was aspirated and each well was washed twice with
B1 mL of Phosphate Buffered Saline (PBS) to remove trace
media and the wash solution aspirated. The RPTEC/TERT1
cells were harvested by the addition of 1 mL of methanol to
each well (methanol quenching),14 scraping and transferred to
an Eppendorft tube. Each well was washed again with 1 mL
of methanol and the two samples pooled. The pooled methanol
quenched sample (2 mL) was dried under a flow of nitrogen
gas at room temperature and stored at 80 1C for subsequent
extraction.
Immunofluorescent microscopy
E-cadherin and Zonula Occludin-1 (ZO-1) protein expression
was visualised using indirect immunofluorescence. Briefly,
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8-chamber slides and cultured for 10 days. Cells were fixed
using 3.7% formaldehyde/PBS and then permeabilised with
0.2% (v/v) Triton X-100/PBS. For staining cells were incubated
with the respective primary antibody (1 : 200—ZO-1 (Zymed),
1 : 400—E-cadherin (Molecular Probes)) for 2 hours at room
temperature. Cells were then incubated with a 1 : 200 dilution
of the appropriate Alexa488 conjugated secondary antibody
(Molecular Probes, Invitrogen). Nuclei were stained using
40,6-diamidino-2-phenylindole dihydrochloride (DAPI). Slides





Aqueous soluble metabolites were extracted from cultured
RPTEC/TERT1 cells using a chloroform/methanol/water
extraction method. Briefly, 300 mL of chloroform/methanol
(2 : 1) solution was added to each Eppendorft tube containing
the dried methanol quenched sample. The sample was then
vortex mixed for 30 seconds, 300 mL of ultrapure water added
and vortex mixed again. The sample was centrifuged (16 000g,
10 min) and the aqueous and organic layers removed to
separate sample tubes (the organic phase was not analyzed
in the present study). The extraction process was repeated for
each sample and the aqueous sample pooled and left to
evaporate at room temperature for B12 hours to remove
any organic solvent. The aqueous extract was then freeze
dried, reconstituted in 600 mL of phosphate buffer (0.2 M
Na2HPO4, 0.043 M NaH2PO4, 100 mM TSP, 3 mM NaN3 in
100% D2O) and centrifuged (16 000g, 5 min); of which 550 mL
was transferred to a standard 5 mm glass NMR tube for
spectroscopic analysis.
The culture media was prepared for spectroscopic analysis
by the addition of 50 mL of D2O (containing 0.2% TSP (w/v))
to 550 mL of media sample, vortex mixed and 550 mL
(TSP: 0.97 mM) transferred to a standard 5 mm glass NMR tube.
All reagents were checked prior to sample preparation by
obtaining a 1D 1H NMR spectrum to ensure that they contain
no contaminants that may interfere with the downstream
spectroscopic analysis.
1H NMR spectroscopy
High-resolution, 1D, 1H NMR spectra of reconstituted intra-
cellular aqueous extracts and culture media were acquired at
14.1 T (600.13 MHz 1H frequency) using a Bruker AVANCE
600 spectrometer (Bruker Biospin, Rheinstetten, Germany). A
5 mm broadband-inverse tube probehead held at 300 K was
used for all NMR experiments. A BACS 60 automated sample
changer (Bruker BioSpin) was used for sample management
during the analytical run, with acquisitions controlled using
Xwin-NMR/Icon-NMR (Bruker Biospin). All spectra were
acquired from randomised cellular or media samples. Following
sample introduction to the probehead, gradient shimming was
used to improve the magnetic field homogeneity. Carr–Purcell–
Meiboom–Gill (CPMG) 1H spectra were acquired using the
pulse sequence (RD-901-[t-1801-t]n-AQ). The fixed echo time,
t was set to 400 ms, giving a total spin-echo time of 64 ms.
During the acquisition period (AQ, 2.73 s), the free induction
decay (FID) was recorded into 64 k data-points in the time
domain, with a spectral width of 20 ppm. Typically, spectra
were recorded as the sum of 128 transients following 16
dummy scans. In both cases, suppression of the water resonance
centered at dH= 4.7 ppm was achieved by the application of a
presaturation pulse during the relaxation delay (RD, 3 s).
Prior to Fourier transformation, all FIDs were multiplied by
an exponential function equivalent to a line broadening of
0.3 Hz. Assignment of resonances to specific metabolites was
based on the Chenomx profiler in the NMR suite 6.1 software
(Chenomx Inc, Alberta, Canada), on the addition of known
standards to the biological samples, published literature,15
in-house assignment databases and statistical total correlation
spectroscopy16 (STOCSY).
NMR data and statistical analysis
Data were imported and manipulated in Matlab (Mathworks)
using in-house software written and compiled by Dr T. M. D.
Ebbels, Dr H. C. Keun, Dr J. T. Pearce, and Dr R. Cavill. 1H
NMR spectra were automatically phased, baseline corrected,
and referenced and normalised to the TSP resonance at d 0.
For all subsequent analysis culture media data were normalised to
TSP but the aqueous intracellular fraction data were
normalised to the median fold change.17 The spectra were
digitized using Matlab script developed in-house. Two levels
of data resolution were analyzed: full resolution spectra at
32 697 data points and reduced resolution spectra that
comprised of 166 (intracellular fraction) and 96 (media) data
points of varying ppm width. The data points in the reduced
resolution data for both the intracellular and media analysis
were created using a targeted binning approach. After
metabolite identification (see previous section) manually
selected regions of the full resolution spectra were integrated,
where possible if a metabolite had multiple resonances they
were integrated together in a single region, and unassigned
resonances were also integrated. Manual integration reduces
the signal multiplicity of a metabolite as multiple resonances
from the same molecule can be integrated together, chemical
shift can be corrected in some cases by integrating a larger
spectrum width and almost all the empty regions of the
spectrum are removed. Resonances that were identified as a
treatment compound were removed from the analysis (both
intracellular and media), as were resonances that were only
present in a single batch or treatment group, were unable to be
identified as a metabolite and demonstrated no time response.
D-Mannitol was the only dosing compound which was detectable
in the study, in both the intracellular fraction and the culture
media. The low concentration (IC10) of the other compounds
meant that they were present at levels below the limit of
detection of the 1H NMR spectroscopy we performed.
For multivariate analysis the reduced resolution data were
exported to SIMCA-P (Umetrics, USA). Principal Component
Analysis (PCA) was applied to the reduced resolution data
(intracellular and media) to reveal treatment related effects, as
well as monitoring RPTEC/TERT1 metabolic response over
time (6–72 h) or batch (2 batches) related effects. A batch
related effect was observed in both the intracellular fraction
and the culture media. To correct for this batch effect all
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each batch included 3 toxins and a matched control; Batch 1:
control 1, nifedipine, potassium bromate, monuron and
batch 2: control 2, D-mannitol, ochratoxin A, sodium diclofenac.
A time related effect was also observed in both batches over
the 72 h time course of the study.
Relative concentrations of media metabolites were
converted to a concentration (mM) using the integrated TSP
region (0.97 mM). Both the relative intracellular concen-
trations and media mM concentrations were expressed as
change from matched control, where control concentration
is equal to one, and the standard error of the mean calculated.
Results
In order to define the metabolome of the RPTEC/TERT1
model and the impact on global metabolic profiles of toxicant
exposure, cells were cultured with either the dosing vehicle
(DMSO) or with exposure to one of six compounds several of
which are known to cause renal effects. These chemicals were
selected from the carcinoGENOMICS project phase I model
compound list13 and included a mixture of toxicants,
primarily human carcinogens (monuron—MON; ochratoxin
A—OTA; and potassium bromate—KBrO3), non-toxins with
pharmacological activity (sodium diclofenac—DIC; nifedipine—
NIF) and one non-toxic control (D-mannitol—MAN). These
compounds do not require metabolic activation and the site of
action for all is exclusively, or includes, the kidney.13 For this
metabolomic study exposures of minimal cytotoxicity (10% of
the Inhibitory Concentration (IC10)) were selected on the basis
of both resazurin (Alamar Bluet) reduction and lactate
dehydrogenase (LDH) release. Where an IC10 could not be
accurately determined, as in the case of D-mannitol, a default
concentration of 10 mM was used. The IC10 values were
determined for the other 5 compounds to be 200 mM
(MON), 300 nM (OTA), 1 mM (KBrO3), 30 mM (DIC) and
10 mM (NIF). RPTEC/TERT1 cells (with metabolism
quenched by methanol, see Methods) and culture media were
harvested at 6, 24 and 72 hours of exposure. Media was
centrifuged and the supernatant frozen while cells were
extracted post harvest using a chloroform/methanol/water
extraction. The aqueous portion of this extract and culture
media were profiled using 1D 600 MHz 1H NMR spectro-
scopy using standard protocols and annotated using a
combination of prior literature and currently available
metabolome databases.
RPTEC/TERT1 morphology has been shown to be similar
to primary RPTECs12 by the formation of dome structures
and the expression of E-cadherin and Zonula Occluden-1. The
RPTEC/TERT1 cells in the present study also demonstrated
these characteristics (Fig. 1A–D). Representative 1D spectra
(CPMG spin echo) of both the RPTEC/TERT1 intracellular
extract and media samples are shown in Fig. 1 (E and F), with
resonances from all identified metabolites highlighted. In total
20 metabolites could be identified in each of the two sample
types, 8 of which were common to both matrices. Most of the
intracellular metabolites detected are common to 1H NMR
analysis of other epithelial cell cultures and observed in
1H MAS-NMR analysis of intact renal tissue. Interestingly,
the metabolite betaine was observed to be at high intracellular
abundance and consistently produced the highest intensity
resonance in all spectra from control extract samples. Betaine,
together with myo-inositol and glycerophosphocholine are
typically observed in high abundance in renal tissue8,18,19
and non-tumour animal renal lines9 by NMR where they play
an osmoprotective/osmoregulatory role.
To characterise the global impact of compound exposure on
the metabolite profile we used a pattern recognition approach
based on PCA of normalised peak integrals for all observable
and resolvable features (166 and 96 for intracellular and
extracellular profiles respectively) in the NMR data. Samples
for this study were generated in two separate experiments each
containing vehicle controls but with different treatments,
hence two models were generated at every time point analysing
data from each experiment separately to remove the influence
of any ‘batch’ effect on the analysis. Pattern recognition
analysis revealed that all of the treatments examined produced
consistent perturbations from vehicle controls in terms of the
intracellular metabolite profile in at least one time point. As all
the toxicants (MON, OTA, KBrO3) produced such effects at
72 h we focussed on models from this time point to assist with
the process of selecting key metabolites that could report on
potential toxicity in this model (Fig. 2A–D). Loading plots for
PCA models from each experimental batch were very similar
indicating that the same metabolites were co-varying in both
sets of exposures. From the effect on PC1 (the first principal
component) scores it appeared that MON decreased levels of
betaine while increasing levels of GPC, alanine, glutamate,
glutamine and glutathione. OTA appeared to produce an
opposite effect to MON, while the non-toxin DIC produced
a broadly similar response in this component. KBrO3 caused a
separation in an orthogonal component, and thus affected
a different set of metabolites, specifically decreasing phospho-
choline, and myo-inositol. Neither of the remaining non-
toxins produced a consistent perturbation from control
at this timepoint. A similar analysis of the extracellular
medium at 72 h showed that only MON and DIC produced
a consistent perturbation from control, in both cases an
apparent increase in lactate production and glucose consumption
(Fig. 2E–H). However other metabolites were observed to
cause significant variation in the extracellular profiles:
3-hydroxyisovalerate (3-HV), alanine, pyruvate, 5-oxoproline
(pyroglutamate), isoleucine, lysine, glutamine, phenylalanine,
tyrosine, tryptophan, threonine and leucine.
To define more quantitatively the effect of chemical
exposure on this metabolite panel, resonances associated with
each metabolite were integrated and the fold change in
normalised intensity relative to matched vehicle control was
calculated at each time point for all treatments. While the
majority (116/180) of treatment effects observed for the
intracellular panel were of low magnitude (o|1.2| fold), five
metabolites exhibited major changes (>|1.5| fold) in intra-
cellular levels for at least one experimental condition: lactate,
alanine, GPC, choline and betaine (Table 1). From the
extracellular metabolite panel, six metabolites exhibited major
differences in extracellular concentration compared to controls
at the end of the experiment (72 h) for at least one condition:
lactate, alanine, isoleucine, tryptophan, pyruvate and
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Fig. 1 RPTEC/TERT1 cells were grown to confluency in 6-well plates or Falcon chamber slides, and cultured for 10 days. (A and B) Cell morphology
was assessed by phase contrast microscopy at 100 MAG (A) and 200 MAG ((B) arrows indicate fluid-filled domes). E-cadherin (C) and Zonula
Occluden-1 (ZO-1(D)) protein expression was visualised using indirect immunofluorescence and a confocal microscope as described in materials and
methods (630 MAG). Typical full resolution 600 MHz 1H CPMG spin-echo NMR spectra (median fold change normalised) of aqueous intracellular
extract (E) and culture media (F) in a representative spectrum of the RPTEC/TERT1 cell line. Spectra shown are from the control group of batch 1.
Metabolites: 1: Isoleucine, 2: Leucine, 3: Valine, 4: EtOH, 5: Threonine, 6: Lactate, 7: Alanine, 8: Lysine, 9: 5-Oxoproline, 10: Glutamine, 11: Pyruvate, 12:
DMSO, 13: Tyrosine, 14: Glucose, 15: Myo-inositol, 16: Histidine, 17: 1-methylnicotinamide, 18: NAD+/NADP+, 19: Tryptophan, 20: Contaminant,
21: GSSG, 22: b-alanine, 23: GSH, 24: Aspartate, 25: Phosphocholine, 26: Glutamate, 27: Phenylalanine, 28: Glycerophosphocholine, 29: Betaine,
30: Glycine, 31:MeOH, 32: ATP/ADP/AMP, 33: Formate, 34: Phenol. Aromatic region (5.8–9.5 ppm) in the spectrum of the intracellular fraction (E) is at
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distributed across the different treatments: MON produced the
greatest number of effects, followed by two other toxicants
OTA and DIC, while KBrO3, NIF and MAN produced the
fewest major changes. Furthermore, significant variation was
observed between treatments in the direction and magnitude
of metabolic perturbations. Hence each chemical exposure
appeared to produce a distinct pattern of metabolic responses,
reflecting the diversity in the biological properties of the
Fig. 2 The response of the RPTEC/TERT1 cell line to specific toxins at 72 hours in both the aqueous cellular extract and the culture medium.
Principal component analysis (PCA) was applied to the intracellular and media metabolic profiles to assess treatment related effects. The reduced
resolution data (intracellular = 166 data points/media = 96 data points of varying ppm width) were Pareto scaled in all models. NIF—Nifedipine,
KBrO3—Potassium Bromate, MON—Monuron, MAN—D-Mannitol, OTA—Ochratoxin A, DIC—Sodium Diclofenac. PCA scores plots (A, E,
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compounds tested in this study. These are described in further
detail below and a complete list of all observed perturbations
to the targeted metabolite panel for all experimental
conditions is available online (ESIw, Table S1).
Perturbations to renal osmolytes and choline metabolism
Fig. 3A and B presents treatment-related effects to intra-
cellular betaine and GPC levels across all treatment conditions.
While GPC and betaine are both abundant renal osmolytes
and accumulate with increases in extracellular tonicity, we
observed both increases and decreases in intracellular
levels and a lack of coordination in response between these
metabolites across treatments, indicating that perturbations to
osmoregulation and/or non-specific osmotic stress were
unlikely to be primarily responsible for these metabolite
changes. Intracellular levels of betaine, likely to reflect a
normal, differentiated renal epithelial phenotype, were generally
observed to be lower after treatment, with major decreases
observed in cells exposed to monuron (up to 4-fold, p= 0.003,
72 h) and DIC (up to 1.9 fold, p = 0.05, 72 h). OTA was the
only treatment to cause an increase in betaine (1.29 fold,
p = 0.1, 72 h). Levels of choline metabolites are well known
to be altered in states of hyperproliferation, e.g. in malignancy,
and we have previously reported decreases in intracellular
GPC in cultured rat hepatocytes as a result of inhibiting entry
into cell cycle.10 In the current study most treatments caused
minor reductions in GPC, with a major decrease observed for
NIF (up to 2.1-fold, p = 0.02, 24 h). Interestingly, two
carcinogens exhibited the opposite response, with major
increases in GPC observed after exposure to MON (up to
1.76 fold, p = 0.0008, 72 h) and lesser increases observed in
OTA exposed cells at earlier timepoints (up to 1.28 fold,
p = 0.04, 6 h). This implied that exposure to these specific
compounds at a low, non-toxic dose produced a metabolic
state associated with promotion of proliferation and survival.
Choline is a precursor to both betaine and GPC which is not
directly synthesised but is instead taken up from the culture
medium. However perturbations to intracellular choline levels
(Fig. 3C) were not generally correlated to either GPC or
betaine levels, and did not distinguish clearly toxicants from
non-toxicants. Decreases were observed in choline levels for
four treatments at 72 h: NIF (1.4 fold, p = 0.005, 72 h),
KBrO3 (1.3 fold, p = 0.02, 72 h), MON (2.6 fold, p = 0.01,
72 h) and MAN (1.9 fold, p = 0.6, 72 h). MON exposure
produced the greatest fall in both choline and betaine levels, so
it was possible that for particular treatments reduced choline
uptake and subsequently choline availability contributed to
alterations in other metabolites. Generation of betaine from
choline involves the mitochondrial enzymes choline oxidase
and betaine aldehyde dehydrogenase. Thus variation in
betaine may also reflect perturbations to mitochondrial
metabolism.
Perturbations to glycolysis, the fate of pyruvate and
mitochondrial metabolism
Glucose is the primary energy substrate for cultured mammalian
cells and after absorption from the extracellular medium is
converted to pyruvate during glycolysis with concomitant
production of ATP and NADH. We observed major increases
in total amount of glucose removed from the media after 72 h
exposure to MON (2.9 fold, p = 0.03) and DIC (3.0 fold,
p = 0.02). In our study, using low cytotoxic doses, these
alterations in glucose uptake from the culture medium are
likely to reflect specific perturbations in the rate of glycolysis.
In addition to glucose consumption we also observed a net
accumulation of extracellular pyruvate, lactate and alanine.
Cytosolic pyruvate generated by glycolysis has a number of
fates, primarily: transport/diffusion from the cell; anaerobic
conversion to lactate to recover NAD+; oxidation via the
TCA cycle in mitochondria; or conversion to alanine via
transamination with glutamate. Mitochondrial metabolism is
the most energy efficient route, generating up to an additional
36 ATP versus 2 ATP from glycolysis alone. Lactate
accumulation over 72 h was also markedly increased with
both MON (2-fold, p = 0.004) and DIC (2.8 fold, p = 0.007)
exposure. The magnitude of effect observed was comparable to
the increase in glucose uptake with these treatments, suggesting
that both compounds caused an increase in glycolysis without
Table 2 Major extracellular metabolite changes (fold change relative
to control) in the media at 72 hours
Metabolite
Treatment compound
Monuron Mannitol Ochratoxin A Diclofenac
Lactate 2.01  0.05 — — 2.78  0.03
Alanine — — 0.57  0.03 —
Isoleucine 0.59  0.29 — — —
Tryptophan — 0.23  0.11 — 2.66  0.22
Pyruvate — — 1.66  0.03 2.08  0.15
Glucose 0.34  0.01 — — 0.33  0.07
Metabolites shown in the above table exhibited major differences
(>1.5 fold) in extracellular concentration compared to controls
at the end of the experiment (72 h) for at least one condition.
Control = 1.
Table 1 Major intracellular metabolite changes (fold change relative to control)
Metabolite
Treatment compound
Nifedipine Monuron Mannitol Ochratoxin A Diclofenac
Betaine — 0.67 (24 h), 0.25 (72 h) — — 0.53 (72 h)
GPC 0.48 (24 h) 1.76 (72 h) 0.67 (72 h) — —
Lactate — 0.32 (72 h) — 1.61 (6 h), 0.60 (72 h) 1.55 (24 h)
Choline — 0.38 (72 h) 0.52 (72 h) — —
Alanine — 1.62 (72 h) — 0.58 (72 h) —
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substantially increasing the rate of oxidative metabolism and
that much of the excess pyruvate was converted rapidly to
lactate.
While no other treatment produced significant differences in
lactate accumulation by the end of the study, OTA exposure
did produce major decreases in extracellular lactate levels
within the first 24 h (2-fold, p = 0.09) without a substantial
increase in glucose uptake over the same period (1.1 fold,
p = 0.9). This indicated that this compound had a very
different impact on energy metabolism than DIC or MON,
possibly ‘enhancing’ mitochondrial metabolism and increasing
the proportion of pyruvate consumed via oxidation. Supporting
this hypothesis, we observed that OTA was the only treatment
to (a) increase betaine levels, (b) to affect alanine accumulation,
reducing this by 1.7 fold (p = 0.01), and (c) was also the only
exposure which produced NMR-detectable levels of the
metabolite 3-HV (Fig. 3D). 3-HV is the product of irreversible
hydrolysis of 3-methylcrotonyl-CoA an intermediate in
leucine catabolism produced by the mitochondrial enzyme
isovaleryl-CoA dehydrogenase,20,21 and the appearance of this
metabolite is consistent with an overall increase in the rates of
mitochondrial reactions. Finally, major increases in pyruvate
accumulation were observed after 72 h exposure to all three
toxicants, DIC (2.1 fold, p = 0.008), OTA (1.7 fold,
p = 0.006) and to a lesser extent MON (1.4 fold, p = 0.05).
This might result from increased intracellular concentration of
pyruvate which is a plausible consequence of both (a) increased
glycolysis without an increase in oxidation as apparent for
DIC and MON treatment, and (b) suppression of anaerobic
conversion of pyruvate to lactate or alanine with a concomitant
increase in oxidative metabolism as hypothesised for OTA
treatment.
While it was not possible to detect intracellular pyruvate by
1H NMR, we were able to observe major perturbations to
intracellular lactate and alanine levels after treatment with
DIC, OTA or MON, supporting the interpretation that the
pyruvate production is altered with these treatments. However
no consistent relationship was apparent between intracellular
levels of each metabolite, nor between intracellular levels and
extracellular accumulation. One likely contribution to these
discrepancies is the fact that the composition of the extra-
cellular media represents a time-average of the metabolic
behaviour of the cells whereas extraction of intracellular
metabolites provides a ‘snap-shot’ of transient metabolic
status. These temporal relationships are further complicated
by feedback processes, i.e. reuptake of exported metabolites.
For example in our study, lactate accumulation appeared to
peak in control cultures within the first 24 h (0.07 mmol h1),
with a small net consumption of lactate occurring during the
subsequent 48 h in spite of continuing glucose uptake
(0.06 mmol h1 between 6–24 h and 0.03 mmol h1
between 24–72 h). Hence some recycling of extracellular
lactate and other sources of pyruvate was likely in all
treatment conditions and the net accumulation of these
substrates will also be dependent on the capacity for reabsorption
via mono-carboxylate transporters.
Fig. 3 Effect of compound treatment on the concentration of three intracellular metabolites and the effect of ochratoxin A treatment on
extracellular 3-HV concentration. (A) Change in relative concentration (fold change relative to control) of intracellular betaine levels in all six
treatment groups. (B) Change in relative concentration (fold change relative to control) of intracellular GPC levels in all six treatment groups.
(C) Change in relative concentration (fold change relative to control) of intracellular choline levels in all six treatment groups. (D) Averaged
1H CPMG spin-echo NMR spectra (n= 3 per timepoint) showing the increase in 3-HV concentration in the media of OTA treated RPTEC/TERT1
cells. 3-HV = 3-hydroxy-isovalerate. NIF—Nifedipine, KBrO3—Potassium Bromate, MON—Monuron, MAN—D-Mannitol, OTA—Ochratoxin
A, DIC—Sodium Diclofenac. Significance compared to control assessed byWelch’s t-test. NIF, KBrO3 and MON compared to control 1 and MAN,
OTA and DIC compared to control 2. Control = 1. Significance marked as: *p o 0.05, **p o 0.01, ***p o 0.001. Significance values indicated are
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Perturbations to glutathione metabolism
While glutathione could be detected by 1H NMR of cell
extracts, it was not possible to distinguish between oxidised
(GSSG) and reduced (GSH) forms of the molecule. Two
treatments increased the total glutathione pool, MON (1.32
fold, p = 0.02, 72 h) and OTA (1.23 fold, p = 0.02, 72 h),
which may reflect a tendency to increased proliferation. No
treatment produced a decrease in total glutathione abundance.
Levels of 5-oxoproline, an intermediate in the recycling of
cysteine from GSH,22 was also observed to accumulate in the
culture medium. 5-Oxoproline is a cyclic lactam form of
glutamate that accumulates upon exposure to glutathione
depleting toxicants (e.g. bromobenzene)19 and in congenital
defects such as glutathione synthase deficiency23 and
oxoprolinase deficiency associated with oxidative stress,
metabolic acidosis, neurotoxicity.22 While no differences were
observed in 5-oxoproline accumulation at the end of the study,
a minor increase was detected after 24 h of exposure to
nifedipine (1.25  0.02, 24 h) and potassium bromate
(1.31  0.02, 24 h). This could indicate that these treatments
caused a transient increase in GSH turnover and an increase in
oxidative stress. However, 5-oxoproline can also form from
spontaneous cyclisation of glutamine in aqueous solution, a
reaction made more favourable by non-physiological pH.
Hence these effects could reflect a transient shift in acid/base
balance during culture.
Discussion
Our data show that metabolic profiling of RPTEC/TERT1
cells can report on the effect of chemical exposure on multiple
cellular pathways at low-level exposure, producing different
response profiles for the different chemicals tested. Importantly,
compounds with established links to chronic renal toxicity
produced more diverse and severe perturbations to the cellular
metabolome than non-toxic compounds in this model. An
over view of the major metabolic changes and how they are
associated with chemical treatments is shown in Fig. 4.
Many of our observations concur with known biological
properties of our chemical panel.
Ochratoxin A is a mycotoxin produced by some fungi and a
common contaminant of foodstuffs. It has been classified as a
carcinogen in the rodent kidney (reviewed in Mally and
Dekant)24 but it’s mechanism of action is unclear as there is
contrasting empirical evidence. However, it seems unlikely
that it is directly genotoxic as there is little evidence for
ochratoxin A–DNA adducts25–28 or 8-oxodG29,30 formation
but it has been suggested that ochratoxin A mutagenesis is
based on oxidative stress.31
At low concentration (nM) OTA has been shown to increase
aerobic metabolism or ‘‘stimulate’’ mitochondria.32 A finding
that is confirmed in our study where we observe a decrease in
extracellular lactate with no accompanying uptake of glucose
and increased excretion of pyruvate and 3-HV. Additionally,
two studies suggest33,34 that OTA impairs antioxidant defence
in the kidney by the down regulation of Nrf-2 dependant gene
expression resulting in abasic site formation in DNA both
in vitro and in vivo. OTA induced aerobic metabolism,
increased according to our findings, and impaired antioxidant
defence would increase oxidative stress via the increased
production and reduced detoxification of H2O2.
A previous metabonomic study carried out in the rat
suggested alteration of energy metabolism and mitochondrial
function when the animals were dosed with 0–210 mg kg1
body weight35 of OTA, where urinary citrate and 2-oxoglutarate
levels were observed to decrease. Additionally, urinary
5-oxoproline (glutathione depletion or oxidative stress)
concentration was increased, which is an effect we do not
observe in the RPTEC/TERT1 in vitro model. Of course, the
rodent study by Sieber et al. represents systemic changes at higher
doses than the present study and OTA is also active in the liver.
The increase in intracellular GPC levels associated with
OTA treatment is suggestive of increased proliferation and
survival, both of which are facets of a malignant cancer
phenotype. MON treatment was more strongly associated
with an increase in cellular proliferation, than OTA, as a
greater increase in intracellular GPC levels was observed,
which may be expected as both MON and OTA are
carcinogenic. MON is a herbicide that causes renal and
hepatic carcinogenesis in the male rat through a non-genotoxic
mechanism of action.36 Treatment of the RPTEC/TERT1 cell
line with MON caused multiple changes to the intracellular
and media metabolite profile, suggesting that processes in
addition to proliferation, were affected. MON, as well as
DIC, both had a negative effect on mitochondrial metabolism.
DIC is a widely used analgesic and anti-inflammatory drug
and can be hepatotoxic,37 with no genotoxic or carcinogenic
action.38 Although MON and DIC are considered as different
classes of compound (MON is considered a carcinogen and
DIC is non-carcinogenic), both show an increase in glycolysis
without an increase in mitochondrial oxidative metabolism.
Considered together, these changes and the decreased amounts
of betaine (both compounds) and choline (MON only) indicate
that mitochondrial metabolism may be perturbed by these
treatments.
Fig. 4 Overview of the intracellular and extracellular metabolic
changes in the RPTEC/TERT1 cell line associated with compound
exposure. Red indicates that the treatment compound increases the
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DIC may also be altering the transportation of lactate and
pyruvate across cellular membranes. In a primary epithelial
cell line39 (human retinal origin) and immortalised cell line40
(human corneal origin) DIC exposure causes activity changes
in the monocarboxylate transporters (SMCT1 and MCT1/
MCT4). These effects are of course observed in a very specific
cell type but SMCT1 and SMCT2 are expressed in the
kidney41 and are involved in lactate and pyruvate transport.
KBrO3 did not cause any ‘‘major’’ changes (o1.5 fold) to
the endogenous metabolic profile of the RPTEC/TERT1 cell
line in the present experiments. In a previous NMR-based
metabonomic study in the rat,42 it was observed that a 2 week
dose of KBrO3 (100 and 200 ppm) caused no treatment related
changes to the endogenous urinary metabolite profile. A minor
increase was detected in extracellular 5-oxoproline levels after
24 h of exposure to NIF and KBrO3. NIF is a dihydropyridine
calcium channel blocker and is used as a antihypertensive
drug43 and KBrO3 induces tumourigenesis in the kidney of
rats and mice,44 and acts at least in part through oxidative
DNA damage.45,46 5-Oxoproline is an intermediate in the
g-glutamyl cycle of glutathione metabolism and a reduction
of GSH synthesis can result in a raised level of 5-oxoproline.22
5-Oxoprolinuria has been observed in rats that have been
dosed with chemicals that induce glutathione or cysteine
depletion.19,47 KBrO3 damages DNA and causes the formation
of 8-oxodG lesions in the rodent kidney48 and NIF has been
shown to be photosensitive and undergo oxidation when
exposed to light.49–51 Both treatments could cause a transient
increase in GSH turnover, whilst not affecting the concentration
of the glutathione pool, and increase oxidative stress.
There are some caveats to the approach used in the current
study to examine the metabolic effects of the treatment
compounds, specifically the quenching of cellular metabolism.
The method used to quench the metabolism of the RPTEC/
TERT1 cells has been shown to improve the recovery of some
metabolites14 in an epithelial cell line but it is not clear if the
quenching efficiency is the same for different cell types. It is
clear that certain metabolites, such as the adenosine phosphate
pool (ATP/ADP/AMP) orNAD+/NADP+, will be particularly
sensitive to quenching and extraction techniques, and it may
be necessary to optimise these methods for each cell line.
Extracellular metabolite measurements are far less difficult
to quench as this is effectively done by removing the media
from the cells, for adherent cell lines such as the RPTEC/
TERT1, which instantly stops the exchange of metabolites
between cells and media. Whereas intracellular metabolite
profiles are a snap-shot of the metabolism at the particular
time of quenching, the extracellular (media) profiles are an
accumulation of the metabolic activity over the period of time
up to the point of collection. It is because of this quenching at
a single time point that the intracellular metabolite profile is
more susceptible to variability due to the timing of sampling.
Media (extracellular metabolites) profiles are more stable as
they represent an accumulation of metabolites over the time
course of the study. Acquisition of a cell culture media NMR
spectrum is quicker than the aqueous fraction as it requires
less preparation in comparison and it may also be possible to
increase the coverage of metabolites detected in culture media
by the use of UPLC- and GC-MS.
By combining metabolomics and in vitro human cell models,
like the RPTEC/TERT1 line, it may be possible to elucidate
the pathways and biological processes that are perturbed by
toxins. The National Research Council (NRC) has developed
a long-range vision and strategy to advance toxicity testing in
the 21st century.1 Here the NRC has referred to ‘‘toxicity
pathways’’, which are the pathways that when sufficiently
perturbed can cause adverse health effects in humans. It is in
systems such as the one utilised in our study (metabolic
profiling and the RPTEC/TERT1 cell system) that these
pathways could be defined and the response to toxicants
characterised.
We suggest that when perturbations to multiple pathways
are observed using metabolic profiling at a low dose a compound
is likely to be toxic to the cell type examined. Furthermore a
response signature that combines an increased tendency to
proliferation and survival, an effect to mitochondrial metabolism
and alterations in key renal osmolytes are an indication that a
compound may be carcinogenic.
Acknowledgements
This study was funded primarily by the EU 6th Framework
grant ‘‘carcinoGENOMICS’’ (PL-037712). This work was also
supported in part by the Conway Institute for Biomolecular and
Biomedical Research, University College Dublin, under the
Programme for Research in Third Level Institutions (PRTLI)
administered by the Higher Education Authority of Ireland.
References
1 S. Gibb, Reprod. Toxicol., 2008, 25, 136–138.
2 J. K. Nicholson, J. C. Lindon and E. Holmes, Xenobiotica, 1999,
29, 1181–1189.
3 O. Fiehn, Plant Mol. Biol., 2002, 48, 155–171.
4 M. Coen, E. Holmes, J. C. Lindon and J. K. Nicholson, Chem.
Res. Toxicol., 2008, 21, 9–27.
5 T. M. Ebbels, H. C. Keun, O. P. Beckonert, M. E. Bollard,
J. C. Lindon, E. Holmes and J. K. Nicholson, J. Proteome Res.,
2007, 6, 4407–4422.
6 E. Holmes, F. W. Bonner, K. P. Gartland and J. K. Nicholson,
J. Pharm. Biomed. Anal., 1990, 8, 959–962.
7 D. Moka, R. Vorreuther, H. Schicha, M. Spraul, E. Humpfer,
M. Lipinski, P. J. Foxall, J. K. Nicholson and J. C. Lindon,
J. Pharm. Biomed. Anal., 1998, 17, 125–132.
8 A. R. Tate, P. J. Foxall, E. Holmes, D. Moka, M. Spraul,
J. K. Nicholson and J. C. Lindon, NMR Biomed., 2000, 13, 64–71.
9 T. Nakanishi, R. S. Balaban andM. B. Burg, Am. J. Physiol., 1988,
255, C181–C191.
10 J. K. Ellis, P. H. Chan, T. Doktorova, T. J. Athersuch, R. Cavill,
T. Vanhaecke, V. Rogiers, M. Vinken, J. K. Nicholson and
M. D. Ebbels, et al., J. Proteome Res., 2010, 9, 413–419.
11 P. L. Smith, D. A. Buffington and H. D. Humes, Methods
Enzymol., 2006, 419, 194–207.
12 M. Wieser, G. Stadler, P. Jennings, B. Streubel, W. Pfaller,
P. Ambros, C. Riedl, H. Katinger, J. Grillari and R.
Grillari-Voglauer, Am. J. Physiol. Renal Physiol., 2008, 295,
F1365–F1375.
13 M. Vinken, T. Doktorova, H. Ellinger-Ziegelbauer, H. J. Ahr,
E. Lock, P. Carmichael, E. Roggen, D. J. van, J. Kleinjans and
J. Castell, et al., Mutat. Res., 2008, 659, 202–210.
14 Q. Teng, W. Huang, T. W. Collette, D. R. Ekman and C. Tan,
Metabolomics, 2009, 5, 199–208.
15 T. W. M. Fan and A. N. Lane, Prog. Nucl. Magn. Reson.




































This journal is c The Royal Society of Chemistry 2011 Mol. BioSyst., 2011, 7, 247–257 257
16 O. Cloarec, M. E. Dumas, A. Craig, R. H. Barton, J. Trygg,
J. Hudson, C. Blancher, D. Gauguier, J. C. Lindon and E. Holmes,
et al., Anal. Chem., 2005, 77, 1282–1289.
17 F. Dieterle, A. Ross, G. Schlotterbeck and H. Senn, Anal. Chem.,
2006, 78, 4281–4290.
18 Y. Wang, M. E. Bollard, J. K. Nicholson and E. Holmes, J. Pharm.
Biomed. Anal., 2006, 40, 375–381.
19 N. J. Waters, C. J. Waterfield, R. D. Farrant, E. Holmes and
J. K. Nicholson, J. Proteome Res., 2006, 5, 1448–1459.
20 K. Daschner, I. Couee and S. Binder, Plant Physiol., 2001, 126,
601–612.
21 J. Vockley and R. Ensenauer, Am. J. Med. Genet., Part C, 2006,
142C, 95–103.
22 S. C. Lu, Mol. Aspects Med., 2009, 30, 42–59.
23 Z. Z. Shi, G. M. Habib, W. J. Rhead, W. A. Gahl, X. He, S. Sazer
and M. W. Lieberman, Nat. Genet., 1996, 14, 361–365.
24 A. Mally and W. Dekant,Mol. Nutr. Food Res., 2009, 53, 467–478.
25 C. Schlatter, J. Studer-Rohr and T. Rasonyi, Food Addit. Contam.,
1996, 13(Suppl), 43–44.
26 J. Gautier, J. Richoz, D. H. Welti, J. Markovic, E. Gremaud,
F. P. Guengerich and R. J. Turesky, Chem. Res. Toxicol., 2001, 14,
34–45.
27 A. Mally, H. Zepnik, P. Wanek, E. Eder, K. Dingley, H. Ihmels,
W. Volkel and W. Dekant, Chem. Res. Toxicol., 2004, 17, 234–242.
28 A. Mally, G. Pepe, S. Ravoori, M. Fiore, R. C. Gupta, W. Dekant
and P. Mosesso, Chem. Res. Toxicol., 2005, 18, 1253–1261.
29 J. C. Gautier, D. Holzhaeuser, J. Markovic, E. Gremaud,
B. Schilter and R. J. Turesky, Free Radical Biol. Med., 2001, 30,
1089–1098.
30 A. Mally, W. Volkel, A. Amberg, M. Kurz, P. Wanek, E. Eder,
G. Hard and W. Dekant, Chem. Res. Toxicol., 2005, 18,
1242–1252.
31 N. Palma, S. Cinelli, O. Sapora, S. H. Wilson and E. Dogliotti,
Chem. Res. Toxicol., 2007, 20, 1031–1037.
32 M. Gekle, C. Sauvant and G. Schwerdt, Mol. Nutr. Food Res.,
2005, 49, 118–130.
33 M. Marin-Kuan, S. Nestler, C. Verguet, C. Bezencon, D. Piguet,
R. Mansourian, J. Holzwarth, M. Grigorov, T. Delatour and
P. Mantle, et al., Toxicol. Sci., 2006, 89, 120–134.
34 C. Cavin, T. Delatour, M. Marin-Kuan, D. Holzhauser,
L. Higgins, C. Bezencon, G. Guignard, S. Junod, J. Richoz-Payot
and E. Gremaud, et al., Toxicol. Sci., 2007, 96, 30–39.
35 M. Sieber, S. Wagner, E. Rached, A. Amberg, A. Mally and
W. Dekant, Chem. Res. Toxicol., 2009, 22, 1221–1231.
36 C. R. Elcombe, J. Odum, J. R. Foster, S. Stone, S. Hasmall,
A. R. Soames, I. Kimber and J. Ashby, Environ. Health Perspect.,
2002, 110, 363–375.
37 U. A. Boelsterli, Toxicol. Appl. Pharmacol., 2003, 192,
307–322.
38 R. D. Snyder and J. W. Green, Mutat. Res., 2001, 488, 151–169.
39 S. Ananth, L. Zhuang, E. Gopal, S. Itagaki, B. Ellappan,
S. B. Smith, V. Ganapathy and P. Martin, Biochem. Biophys.
Res. Commun., 2010, 394, 75–80.
40 K. S. Vellonen, M. Hakli, N. Merezhinskaya, T. Tervo,
P. Honkakoski and A. Urtti, Eur. J. Pharm. Sci., 2010, 39,
241–247.
41 E. Gopal, N. S. Umapathy, P. M. Martin, S. Ananth, J. P. Gnana-
Prakasam, H. Becker, C. A. Wagner, V. Ganapathy and
P. D. Prasad, Biochim. Biophys. Acta, 2007, 1768, 2690–2697.
42 A. Mally, A. Amberg, G. C. Hard and W. Dekant, Toxicology,
2007, 230, 244–255.
43 R. Pontremoli, G. Leoncini and A. Parodi, Expert. Rev.
Cardiovasc. Ther., 2005, 3, 43–50.
44 A. B. DeAngelo, M. H. George, S. R. Kilburn, T. M. Moore and
D. C. Wolf, Toxicol. Pathol., 1998, 26, 587–594.
45 S. Kawanishi and M. Murata, Toxicology, 2006, 221, 172–178.
46 X. Zhang, S. D. De, B. Sun, J. Fisher, R. J. Bull, J. A. Cotruvo and
B. S. Cummings, Toxicology, 2010, 269, 13–23.
47 F. Y. Ghauri, A. E. McLean, D. Beales, I. D. Wilson and
J. K. Nicholson, Biochem. Pharmacol., 1993, 46, 953–957.
48 T. Umemura, A. Takagi, K. Sai, R. Hasegawa and Y. Kurokawa,
Arch. Toxicol., 1998, 72, 264–269.
49 W. A. Al-Turk, I. A. Majeed, W. J. Murray, D. W. Newton and
S. Othman, Int. J. Pharm., 1988, 41, 227–230.
50 I. A. Majeed, W. J. Murray, D. W. Newton, S. Othman and
W. A. Al-Turk, J. Pharm. Pharmacol., 1987, 39, 1044–1046.
51 R. Testa, E. Dolfini, C. Reschiotto, C. Secchi and P. A. Biondi,
Farmaco, Ed. Prat., 1979, 34, 463–473.
Pu
bl
is
he
d 
on
 1
9 
N
ov
em
be
r 
20
10
. D
ow
nl
oa
de
d 
on
 9
/9
/2
02
1 
12
:2
9:
30
 P
M
. 
View Article Online
